Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

128 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I).
Morand EF, Vital EM, Petri M, van Vollenhoven R, Wallace DJ, Mosca M, Furie RA, Silk ME, Dickson CL, Meszaros G, Jia B, Crowe B, de la Torre I, Dörner T. Morand EF, et al. Among authors: vital em. Lancet. 2023 Mar 25;401(10381):1001-1010. doi: 10.1016/S0140-6736(22)02607-1. Epub 2023 Feb 24. Lancet. 2023. PMID: 36848918 Clinical Trial.
Correction: Deconvolution of whole blood transcriptomics identifies changes in immune cell composition in patients with systemic lupus erythematosus (SLE) treated with mycophenolate mofetil.
Akthar M, Nair N, Carter LM, Vital EM, Sutton E, McHugh N; British Isles Lupus Assessment Group Biologics Register (BILAG BR) Consortium; MASTERPLANS Consortium; Bruce IN, Reynolds JA. Akthar M, et al. Among authors: vital em. Arthritis Res Ther. 2023 Sep 4;25(1):160. doi: 10.1186/s13075-023-03160-1. Arthritis Res Ther. 2023. PMID: 37667347 Free PMC article. No abstract available.
Type I interferon pathway assays in studies of rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider.
Burska A, Rodríguez-Carrio J, Biesen R, Dik WA, Eloranta ML, Cavalli G, Visser M, Boumpas DT, Bertsias G, Wahren-Herlenius M, Rehwinkel J, Frémond ML, Crow MK, Ronnblom L, Conaghan PG, Versnel M, Vital E. Burska A, et al. RMD Open. 2023 Mar;9(1):e002876. doi: 10.1136/rmdopen-2022-002876. RMD Open. 2023. PMID: 36863752 Free PMC article.
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update.
Fanouriakis A, Kostopoulou M, Andersen J, Aringer M, Arnaud L, Bae SC, Boletis J, Bruce IN, Cervera R, Doria A, Dörner T, Furie RA, Gladman DD, Houssiau FA, Inês LS, Jayne D, Kouloumas M, Kovács L, Mok CC, Morand EF, Moroni G, Mosca M, Mucke J, Mukhtyar CB, Nagy G, Navarra S, Parodis I, Pego-Reigosa JM, Petri M, Pons-Estel BA, Schneider M, Smolen JS, Svenungsson E, Tanaka Y, Tektonidou MG, Teng YO, Tincani A, Vital EM, van Vollenhoven RF, Wincup C, Bertsias G, Boumpas DT. Fanouriakis A, et al. Among authors: vital em. Ann Rheum Dis. 2024 Jan 2;83(1):15-29. doi: 10.1136/ard-2023-224762. Ann Rheum Dis. 2024. PMID: 37827694
Management and treatment of children, young people and adults with systemic lupus erythematosus: British Society for Rheumatology guideline scope.
Md Yusof MY, Smith EMD, Ainsworth S, Armon K, Beresford MW, Brown M, Cherry L, Edwards CJ, Flora K, Gilman R, Griffiths B, Gordon C, Howard P, Isenberg D, Jordan N, Kaul A, Lanyon P, Laws PM, Lightsone L, Lythgoe H, Mallen CD, Marks SD, Maxwell N, Moraitis E, Nash C, Pepper RJ, Pilkington C, Psarras A, Rostron H, Skeates J, Skeoch S, Tremarias D, Wincup C, Zoma A, Vital EM. Md Yusof MY, et al. Among authors: vital em. Rheumatol Adv Pract. 2023 Dec 5;7(3):rkad093. doi: 10.1093/rap/rkad093. eCollection 2023. Rheumatol Adv Pract. 2023. PMID: 38058676 Free PMC article. Review.
2022 EULAR points to consider for the measurement, reporting and application of IFN-I pathway activation assays in clinical research and practice.
Rodríguez-Carrio J, Burska A, Conaghan PG, Dik WA, Biesen R, Eloranta ML, Cavalli G, Visser M, Boumpas DT, Bertsias G, Wahren-Herlenius M, Rehwinkel J, Frémond ML, Crow MK, Rönnblom L, Versnel MA, Vital EM. Rodríguez-Carrio J, et al. Among authors: vital em. Ann Rheum Dis. 2023 Jun;82(6):754-762. doi: 10.1136/ard-2022-223628. Epub 2023 Mar 1. Ann Rheum Dis. 2023. PMID: 36858821
Co-stimulatory blockade as therapy for rheumatoid arthritis.
Mackie SL, Vital EM, Ponchel F, Emery P. Mackie SL, et al. Among authors: vital em. Curr Rheumatol Rep. 2005 Oct;7(5):400-6. doi: 10.1007/s11926-005-0029-4. Curr Rheumatol Rep. 2005. PMID: 16174492 Review.
128 results